Physician profile
Ryan David Brosch
NPI 1518352376
$1,394.64
in general payments reported to CMS, 2019-2025
23 companies · $317 in 2025
The $317 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.11 · 2021: $131 · 2022: $577 · 2023: $259 · 2024: $86.32 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $649 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $648.51 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $166.83 | 2023-2025 | Acessa Provu System, Myosure Tissue Removal Device, Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Abbvie INC. | $164.67 | 2021-2023 | Lo Loestrin Fe, Orilissa |
| Mayne Pharma Commercial LLC | $133.02 | 2022 | |
| Exeltis, USA INC. | $132.40 | 2021-2023 | Slynd |
| Cook Medical LLC | $125.00 | 2025 | Zilver Ptx |
| Pfizer INC. | $110.19 | 2021-2023 | |
| Intuitive Surgical, INC. | $90.90 | 2022 | |
| Organon LLC | $78.10 | 2022-2023 | Nexplanon |
| Sumitomo Pharma America, INC. | $52.38 | 2023 | Myfembree |
| Amgen INC. | $51.35 | 2023-2024 | Evenity, Prolia |
| Sanara Medtech INC. | $35.65 | 2025 | Celleraterx |
| Millicent US INC | $31.88 | 2019-2024 | Intrarosa, Femring |
| Coopersurgical, INC. | $30.56 | 2021-2022 | |
| Heron Therapeutics, INC. | $25.99 | 2022 | |
| Agile Therapeutics, INC. | $23.89 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $23.18 | 2023 | |
| Meditrina | $19.56 | 2024 | |
| Astellas Pharma US INC | $19.50 | 2025 | Veozah |
| Evofem Biosciences, INC. | $18.94 | 2022 | |
| Renovia INC | $18.58 | 2021 | |
| Smith+Nephew, INC. | $17.50 | 2024 | Pico 14 |
| Minerva Surgical, INC | $13.71 | 2022 | |
| Lupin INC. | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Brosch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.